Deoxycholic acid injection (ATX-101) treatment markedly reduces preplatysmal fat - 21/04/16
Cameron D. Chesnut, MD, University of Washington School of Medicine; Dermatology Specialists of Spokane, Spokane, WA, United States; Nicholas C. Branting, MD, Central Oregon Radiology Associates, Bend, OR, United States; John H. Joseph, MD, The Clinical Testing Center of Beverly Hills, David Geffen School of Medicine, University of California, Los Angeles, Beverly Hills, CA, United States; Todd M. Gross, PhD, Kythera Biopharmaceuticals, Inc, Westlake Village, CA, United States; Paul F. Lizzul, MD, PhD, Kythera Biopharmaceuticals, Inc, Westlake Village, CA, United States; Frederick C. Beddingfield III, MD, PhD, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
Le texte complet de cet article est disponible en PDF.| Supported 100% by Kythera Biopharmaceuticals, Inc. |
Vol 74 - N° 5S1
P. AB15 - mai 2016 Retour au numéro
Article précédent
- Cutaneous sarcoidosis during interferon and ribavirin therapy in a patient with hepatitis C virus infection located at silicone injection sites
- Effect of magnet applicators on niacinamide skin delivery and associated clinical improvements in barrier function
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?